Skip navigation

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

URL of this page: https://medlineplus.gov/genetics/condition/fanconi-anemia/

Fanconi anemia

Description

Fanconi anemia is a condition that is characterized by bone marrow failure, physical differences, organ problems, and an increased risk of certain cancers.

Approximately 90 percent of people with Fanconi anemia have impaired bone marrow function. Bone marrow primarily produces new blood cells. These include red blood cells, which carry oxygen to the body's tissues; white blood cells, which fight infections; and platelets, which are necessary for normal blood clotting. In people with Fanconi anemia, impaired bone marrow function leads to a decrease in the production of all blood cells (aplastic anemia). Affected individuals experience extreme tiredness (fatigue) due to low numbers of red blood cells (anemia), frequent infections due to low numbers of white blood cells (neutropenia), and clotting problems due to low numbers of platelets (thrombocytopenia). People with Fanconi anemia may also develop myelodysplastic syndrome, a condition in which immature blood cells fail to develop normally.

People with Fanconi anemia often have growth problems before or after birth that often result in short stature. Affected individuals can also have irregular skin coloring such as unusually light-colored skin (hypopigmentation) or café-au-lait spots, which are flat patches on the skin that are darker than the surrounding area. People with Fanconi anemia can have skeletal problems that often include malformed thumbs or forearms or an unusually small head size (microcephaly).

Problems in hormone-producing (endocrine) tissues are common in people with Fanconi anemia, including abnormally low levels of thyroid hormones (hypothyroidism), and high blood glucose levels (hyperglycemia). Individuals with Fanconi anemia can also have eye abnormalities such as small or abnormally shaped eyes or malformed or absent kidneys and other defects of the urinary tract.  Less frequent problems include gastrointestinal abnormalities, heart defects, brain abnormalities, and hearing loss. People with Fanconi anemia may have abnormal genitalia or malformations of the reproductive system, which can result in difficulty having biological children (infertility).

Individuals with Fanconi anemia have an increased risk of developing a cancer of blood-forming cells called acute myeloid leukemia (AML). They are also at risk of developing tumors of the liver, gastrointestinal system, genital tract, or head and neck (known as head and neck squamous cell carcinoma). The likelihood of a person with Fanconi anemia developing one of these cancers is between 10 and 30 percent.

Frequency

Fanconi anemia occurs in 1 in 100,000 to 160,000 individuals worldwide. The condition is more common among certain populations, including people of Ashkenazi Jewish descent, the Roma population of Spain, the Afrikaner population of South Africa, and the Japanese population.

Causes

Variants (also called mutations) in more than 20 genes can cause Fanconi anemia. The proteins produced from these genes are involved in a process known as the Fanconi anemia (FA) pathway. The FA pathway turns on (activates) when the process of making new copies of DNA, called DNA replication, is blocked due to DNA damage. The FA pathway triggers DNA repair so DNA replication can continue.

The FA pathway prevents a certain type of DNA damage known as interstrand cross-links (ICLs). ICLs are abnormal connections between two DNA building blocks (nucleotides) on opposite strands of DNA. These cross-links stop the process of DNA replication and can be caused by a buildup of toxic substances produced in the body or by treatment with certain cancer therapy drugs (sometimes known as DNA cross-linking agents).

Eight proteins associated with Fanconi anemia group together to form part of a complex known as the FA core complex. The FA core complex activates two proteins, called FANCD2 and FANCI. The activation of these two proteins brings DNA repair proteins to the area of the ICL so the cross-link can be removed and DNA replication can continue.

Eighty to 90 percent of cases of Fanconi anemia are due to variants in one of three genes: FANCA, FANCC, and FANCG. These genes provide instructions for producing components of the FA core complex. Variants in any of the genes associated with the FA core complex prevent the complex from functioning properly and disrupt the FA pathway. As a result, DNA damage is not repaired efficiently and ICLs build up over time. The ICLs impair DNA replication, which leads to either abnormal cell death due to an inability to make new DNA molecules or uncontrolled cell growth due to a lack of DNA repair. 

Cells that divide quickly, such as bone marrow cells and cells of the developing fetus, are particularly sensitive to problems with DNA replication. The death of these cells results in the decrease in blood cells and the physical differences that are seen in people with Fanconi anemia. When the buildup of errors in DNA leads to uncontrolled cell growth, affected individuals can develop acute myeloid leukemia or other cancers.

Learn more about the genes associated with Fanconi anemia

Additional Information from NCBI Gene:

Inheritance

Fanconi anemia is typically inherited in an autosomal recessive pattern, which means both copies of the gene in each cell must have a variant to cause the disorder. The parents of an individual with an autosomal recessive condition each carry one copy of the altered gene, but they typically do not show signs and symptoms of the condition.

Very rarely, Fanconi anemia is inherited in an autosomal dominant pattern or in an X-linked pattern. An autosomal dominant pattern of inheritance means one copy of the altered gene in each cell is sufficient to cause the disorder. X-linked inheritance means the altered gene is located on the X chromosome, one of the two sex chromosomes in each cell. In individuals who have one X chromosome (typical for males), a variant in the only copy of the gene in each cell is sufficient to cause the condition. In people who have two copies of the X chromosome (typical for females), one altered copy of the gene typically does not cause the condition. A characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons.

Other Names for This Condition

  • FA
  • Fanconi hypoplastic anemia
  • Fanconi pancytopenia
  • Fanconi panmyelopathy

Additional Information & Resources

Genetic Testing Information

Genetic and Rare Diseases Information Center

Patient Support and Advocacy Resources

Clinical Trials

Catalog of Genes and Diseases from OMIM

Scientific Articles on PubMed

References

  • Auerbach AD. Fanconi anemia and its diagnosis. Mutat Res. 2009 Jul 31;668(1-2):4-10. doi: 10.1016/j.mrfmmm.2009.01.013. Epub 2009 Feb 28. Citation on PubMed or Free article on PubMed Central
  • de Winter JP, Joenje H. The genetic and molecular basis of Fanconi anemia. Mutat Res. 2009 Jul 31;668(1-2):11-9. doi: 10.1016/j.mrfmmm.2008.11.004. Epub 2008 Nov 14. Citation on PubMed
  • Deakyne JS, Mazin AV. Fanconi anemia: at the crossroads of DNA repair. Biochemistry (Mosc). 2011 Jan;76(1):36-48. doi: 10.1134/s0006297911010068. Citation on PubMed
  • Green AM, Kupfer GM. Fanconi anemia. Hematol Oncol Clin North Am. 2009 Apr;23(2):193-214. doi: 10.1016/j.hoc.2009.01.008. Citation on PubMed
  • Hoover A, Turcotte LM, Phelan R, Barbus C, Rayannavar A, Miller BS, Reardon EE, Theis-Mahon N, MacMillan ML. Longitudinal clinical manifestations of Fanconi anemia: A systematized review. Blood Rev. 2024 Nov;68:101225. doi: 10.1016/j.blre.2024.101225. Epub 2024 Aug 2. Citation on PubMed
  • Kee Y, D'Andrea AD. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev. 2010 Aug 15;24(16):1680-94. doi: 10.1101/gad.1955310. Citation on PubMed or Free article on PubMed Central
  • Kitao H, Takata M. Fanconi anemia: a disorder defective in the DNA damage response. Int J Hematol. 2011 Apr;93(4):417-424. doi: 10.1007/s12185-011-0777-z. Epub 2011 Feb 18. Citation on PubMed
  • Mathew CG. Fanconi anaemia genes and susceptibility to cancer. Oncogene. 2006 Sep 25;25(43):5875-84. doi: 10.1038/sj.onc.1209878. Citation on PubMed
  • Mehta PA, Ebens C. Fanconi Anemia. 2002 Feb 14 [updated 2021 Jun 3]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. Available from http://www.ncbi.nlm.nih.gov/books/NBK1401/ Citation on PubMed
  • Neveling K, Endt D, Hoehn H, Schindler D. Genotype-phenotype correlations in Fanconi anemia. Mutat Res. 2009 Jul 31;668(1-2):73-91. doi: 10.1016/j.mrfmmm.2009.05.006. Epub 2009 May 21. Citation on PubMed
  • Peake JD, Noguchi E. Fanconi anemia: current insights regarding epidemiology, cancer, and DNA repair. Hum Genet. 2022 Dec;141(12):1811-1836. doi: 10.1007/s00439-022-02462-9. Epub 2022 May 21. Citation on PubMed
  • Taniguchi T, D'Andrea AD. Molecular pathogenesis of Fanconi anemia: recent progress. Blood. 2006 Jun 1;107(11):4223-33. doi: 10.1182/blood-2005-10-4240. Epub 2006 Feb 21. Citation on PubMed

The information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.